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ABSTRACT During the ongoing coronavirus disease 2019 (COVID-19) outbreak, ro-
bust detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a
key element for clinical management and to interrupt transmission chains. We
organized an external quality assessment (EQA) of molecular detection of SARS-CoV-
2 for European expert laboratories. An EQA panel composed of 12 samples, contain-
ing either SARS-CoV-2 at different concentrations to evaluate sensitivity or other re-
spiratory viruses to evaluate specificity of SARS-CoV-2 testing, was distributed to 68
laboratories in 35 countries. Specificity samples included seasonal human coronavi-
ruses hCoV-229E, hCoV-NL63, and hCoV-OC43, as well as Middle East respiratory syn-
drome coronavirus (MERS-CoV), SARS-CoV, and human influenza viruses A and B.
Sensitivity results differed among laboratories, particularly for low-concentration
SARS-CoV-2 samples. Results indicated that performance was mostly independent of
the selection of specific extraction or PCR methods.
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As of December 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 66 million individuals and caused more than 1,500,000 deaths
globally (https://covid19.who.int/; accessed 7 December 2020). As both specific medi-
cations and approved vaccines are not available yet, public health strategies need to
focus on containment and mitigation measures. Robust detection of acute SARS-CoV-
2-infected individuals, typically done by real-time reverse transcription PCR (rRT-PCR),
is crucial for clinical management, surveillance and to interrupt transmission chains (1).
An established tool to improve and support diagnostic accuracy for clinical manage-
ment and surveillance use is the conduction of external quality assessments (EQA)
(2–5). An EQA of molecular detection of SARS-CoV-2 was organized for the expert labo-
ratories of the Emerging Viral Diseases–Expert Laboratory Network (EVD-LabNet) and/
or the European Reference Laboratory Network for Human Influenza (ERLI-Net).
MATERIALS ANDMETHODS
Panel composition. The EQA panel was composed of 12 samples containing either SARS-CoV-2 at
different concentrations to evaluate sensitivity or other respiratory viruses to evaluate specificity of
SARS-CoV-2 testing (Table 1).
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Specimen preparation. SARS-CoV-2 samples were quantified using an E-gene-based in-house assay
recommended by the WHO (6) that relies on an in vitro-transcribed RNA standard. Samples were diluted
in Dulbecco’s modified Eagle’s medium (DMEM). All samples were heat-inactivated following
Matheeussen et al. (4) (65°C for 4 h for SARS-CoV, SARS-CoV-2, MERS-CoV, and adenovirus, and for 2 h
for all other viruses listed in Table 1), and 200ml of each sample was freeze-dried.
Panel validation, testing instructions, and panel dispatch. Successful inactivation of panel sam-
ples was confirmed by the absence of viral growth in three consecutive cell culture passages. Along
with the EQA panels, participants received detailed reconstitution and testing instructions. The panels
were shipped at ambient temperature. If national legislation of a country prohibited receipt of inacti-
vated SARS-CoV and MERS-CoV samples, the laboratories received a modified panel that excluded these
sample(s). Two independent laboratories validated the composition of the EQA panel and the result sub-
mission platform before distribution to all other EQA participants.
Evaluation of results. Result reporting was done via an online submission form by which laborato-
ries could score their samples (positive, negative, or inconclusive) and provide information such as cycle
threshold (CT) values, extraction methods and type of PCR(s). Laboratories were asked to treat and evalu-
ate the EQA samples according to their routine diagnostic workflow, which could include the use of mul-
tiple assays. To ensure uniform interpretation, a sample was scored as positive if at least one SARS-CoV-2
test gave a positive result. No CT threshold was applied.
Sample no. 9, containing SARS-CoV, was not considered a “core sample,” and was therefore not
included in the laboratory performance analysis. Core samples are defined as clinically relevant samples
for proficiency testing. Clinical relevancy was given for the detection of all SARS-CoV-2 samples and for
distinction of SARS-CoV-2 samples from other human respiratory viruses that are circulating in the
human population. Since SARS-CoV has not been circulating in the human population since 2004, the
capability to distinguish between SARS-CoV and SARS-CoV-2, which are closely related, is informative
but unnecessary (7).
EQA participants were only asked to report whether samples were SARS-CoV-2 positive or not.
Statistical analysis. Statistical analyses were conducted to examine if the overall EQA performance
correlated with specific technical details provided by the EQA participants. The information about work-
flows and protocols provided by the EQA participants was reviewed to be conclusive regarding applied
TABLE 1 EQA panel composition and correct test results of participating laboratories
Sample ID Virusa No. of copies/ml
Correct resultsb
% No./total
1 SARS-CoV-2 2 60 41/68
2 SARS-CoV-2 12.5 99 67/68
3 HMPV A 500 96 65/68
HMPV B 2,000 96 65/68
PIV1 2,000 96 65/68
PIV2 2,000 96 65/68
PIV3 2,000 96 65/68
PIV4 2,000 96 65/68
RSV 1,500 96 65/68
4 MERS-CoV 5,000 98 65/66
5 Enterovirus B (Echovirus 6) 2,000 100 68/68
Rhinovirus (Tu-12-1331 HRV A) 1,000 100 68/68
Influenzavirus A 2,000 100 68/68
H1N1 pdm09 500 100 68/68
Influenzavirus B 2,000 100 68/68
Adenovirus 2,000 100 68/68
6 SARS-CoV-2 2 60 41/68
7 hCoV-229E 1,000 97 66/68
hCoV-NL63 2,000 97 66/68
8 hCoV-OC43 2,000 97 66/68
9 SARS-CoV 5,000 89 59/66
10 SARS-CoV-2 12.5 90 61/68
11 SARS-CoV-2 2,500 99 67/68
12 SARS-CoV-2 180 99 67/68
aEnterovirus, rhinovirus, respiratory syncytial virus (RSV), adenovirus, influenza A virus H1N1, influenza B virus,
middle east respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus
(SARS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BetaCoV/Munich/ChVir984/
2020 were grown on Vero cells. Parainfluenza virus 1 (PIV1), parainfluenza virus 2 (PIV2), parainfluenza virus 3
(PIV3), parainfluenza virus 4 (PIV4), human coronavirus 229E (hCoV-229E), and human coronavirus OC43 (hCoV-
OC43) were grown on CaCo-2 cells. Human metapneumovirus A (hMPV A), human metapneumovirus B (hMPV
B), and human coronavirus NL63 (hCoV-NL63) were grown on LLC-MK2 cells.
bLaboratories were not asked to identify the specific viruses, only to indicate whether the samples were SARS-
CoV-2 positive or not.
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FIG 1 Participating laboratories in SARS-CoV-2 molecular EQA and laboratory performance in relation to specific factors. (A) Overview of countries of the
participating laboratories in SARS-CoV-2 molecular EQA, June and July 2020. (B) Numbers of correct, false-negative, and false-positive samples per
laboratory. (C) Reported CT values per SARS-CoV-2-positive sample considering all results reported, including multiple tests conducted by one participant.
Median CT values are indicated by bars, quartiles by boxes, and interquartile range by whiskers. Median CT values were 25.9 (95% confidence interval
(Continued on next page)
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kits or tests. If needed, participants were contacted to confirm or specify the provided information.
Nevertheless, the reported information was not complete for all participants. The utilized data sets did
thus differ slightly in size among statistical analyses of different variables. Before conducting statistical
analyses, variables were tested for normal distribution using the Shapiro-Wilk test. All statistical analyses
were conducted in R version 4.0.2.
Considering the incompleteness of reported information and the high diversity of reported work-
flows (see Fig. S1 in the supplemental material), different steps of the diagnostic workflow were ana-
lyzed individually. For this purpose, each variable was analyzed statistically, including the results of all
EQA participants that provided reliable information for it. For some variables, such as applied PCR assays,
we both tested for a general trend of correlation between the variable and the number of correct results
and compared the amounts of correct results between specifically selected fractions of the variable, e.g.,
comparing the results between two specific real-time RT-PCR assays.
RESULTS
Sixty-eight laboratories from 35 countries, i.e., 28 of 30 European Union/European
Economic Area countries, five of seven European Union preaccession countries, and
two other European countries, reported EQA results (Fig. 1A).
Twenty-seven of 68 participating laboratories tested all core samples correctly (Fig.
1B), 21 reported correct results for 10 samples, and 20 for nine samples or fewer.
Notably, only 37 result submissions were based on the outcome of a single test
method. The remaining participants scored their results based on the outcomes of two
or more test methods. Incorrect results were reported for 9.7% (72/746) of all samples,
with 8.6% (64/746) false-negative results reported for SARS-CoV-2 samples and 1.1%
(8/746) false-positive results reported for specificity controls (Table 1). The risk of false-
negative tests increased significantly with lower SARS-CoV-2 concentrations (P, 0.001;
Spearman correlation test) (Fig. 1C). CT values of correctly tested SARS-CoV-2 samples
increased with decreasing concentration (Fig. 1C). Sixty-three laboratories tested all
specificity samples correctly, while 5 laboratories reported either one or two false-posi-
tive results. No single included respiratory virus was more prone to false-positive test
results than others, pointing to contamination issues rather than issues intrinsic to the
primer/probe sets used (Table 1).
As the performance in an EQA is the outcome of different steps in the diagnostic
workflow combined, preferably different workflows should be compared. These steps
comprise, e.g., resuspension of the panel samples, extraction method/kit used, change
in nucleic acid (NA) concentration during extraction, and type of PCR assay, including
the genomic target and the number of different genomic targets/tests performed.
Among the participants of this EQA, there was an extensive variety of rRT-PCR methods
that was used (Table 2; see also Table S2 in the supplemental material). The number of
diagnostic workflows, which further included the extraction method/kit used and the
RNA concentration change during extraction, was so high that a joint analysis of com-
plete workflows was not possible (see Fig. S1 in the supplemental material), only allow-
ing for analysis of individual components of the workflow.
The performance among laboratories conducting manual NA extraction (92.4% cor-
rect tests) and laboratories conducting automated extraction (89.8% correct tests) did
not differ significantly (P=0.350; Mann-Whitney U test). The EQA performance was not
correlated with the type of extraction kit used (P=0.938; Kruskal-Wallis test) and
ranged between 87.9% and 93.8% correct results (see Table S1 in the supplemental
material). In most extraction protocols NA concentration is increased. However, the
extent of NA concentration was not correlated with diagnostic sensitivity (P=0.898;
Spearman correlation test).
In total, 26 commercial assays and six in-house assays were used by the EQA partici-
pants. Among those assays performed by at least five EQA participants, correct results
FIG 1 Legend (Continued)
[CI], 25.7 to 26.6) for sample 11 (2,500 copies [cps]/ml), 31.6 (95% CI, 31.1 to 32) for sample 12 (180 cps/ml), 34.0 (95% CI, 33.6 to 34.6) for samples 2 and 10
(12.5 cps/ml), and 36.4 (95% CI, 35.6 to 36.9) for samples 1 and 6 (2 cps/ml). Single events are indicated by gray (positive) and purple (negative) dots. (D)
EQA performance, represented as a fraction of correct results (1.0 = 100% correct and 0.8 = 80% correct), depending on different rRT-PCR targets. For box
plot explanation, see panel B.
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ranged between 78% and 92% (Table 2). The performance was not significantly corre-
lated with a type of PCR assay in general (P= 0.525; Kruskal-Wallis test). However,
results were significantly better with the best-performing test (Institute Pasteur, RdRp
gene; Table 2) compared to “Others” (P=0.042; Wilcoxon rank sum test), Corman N
assay (P=0.008), and the Viasure ORF1 assay (P=0.011). The performances among
commercial tests (84.6% correct results) and in-house tests (85.7% correct results) did
not differ significantly (P=0.969; Wilcoxon rank sum test). As transcription in coronavi-
ruses typically varies among different genomic and subgenomic regions, target sites of
the applied assays may affect the diagnostic sensitivity (8). However, the proportion of
correct results did not differ significantly among different genomic targets (P=0.852;
Kruskal-Wallis test) (Fig. 1D).
DISCUSSION
The overall performance within this EQA was variable. Most false results were
reported for low-concentration SARS-CoV-2 samples. While infectious SARS-CoV-2
patients commonly have high viral titers around the first day of illness (9, 10) an opti-
mized diagnostic sensitivity is important to identify patients outside the optimal win-
dow for detection or when sampling or transport were suboptimal (11). Low concen-
trations in clinical samples are also often seen at a later infection stage that coincides
with seroconversion and a drop in infectivity (12). The inclusion of serological tests
such as enzyme-linked immunosorbent assays in diagnostic algorithms when a diagno-
sis is needed for proper patient management and infection prevention measures, e.g.,
in hospitalized patients under strong suspicion of a SARS-CoV-2 infection but with
repeated rRT-PCR-negative results, may reduce the risk of false-negative tests.
Ten laboratories showed problematic EQA performances, including five laboratories
which had false-positive results. Notably, the laboratories reporting false-positive
results applied both extraction kits and rRT-PCR tests also used by other laboratories.
False-positive test results could thus be a consequence of contamination during sam-
ple handling and extraction or lot-specific contamination of rRT-PCR kits or oligonu-
cleotides, as recently reported (13). Either way, laboratories should adapt workflows to
ensure good specificity, which in general was excellent among participants.
Compared to the performance of first-line, routine clinical laboratories in a recently
published SARS-CoV-2 EQA, the sensitivity of participants in our EQA was lower (4).
However, comparing both EQAs is difficult, as sample quantification and preparation
were done differently, in this study more precisely using DMEM instead of transport
TABLE 2 Performance of different rRT-PCR assaysa
rRT-PCR assay (reference) Nb
Method
type Genome target
















Corman et al. (6) 31 In-house E, Sarbeco 100 100 97 87 35
Corman et al. (6) 11 In-house RdRp, SARS-CoV-2 100 100 100 73 18
US CDC, USA (17) 10 In-house N, SARS-CoV-2 100 100 90 70 60
Institute Pasteur, Paris, France (18) 10 In-house RdRp, SARS-CoV-2 100 100 100 90 70
Allplex 2019-nCoV assay 9 Commercial E, Sarbeco 100 89 89 56 44
Allplex 2019-nCoV assay 9 Commercial N, SARS-CoV-2 100 100 78 89 56
Allplex 2019-nCoV assay 9 Commercial RdRp, SARS-CoV-2 100 89 78 67 44
RealStar SARS-CoV-2 RT-PCR kit 1.0 5 Commercial E, Sarbeco 100 100 100 100 40
RealStar SARS-CoV-2 RT-PCR kit 1.0 5 Commercial S, SARS-CoV-2 100 100 100 100 20
Cobas SARS-CoV-2 test 5 Commercial E, Sarbeco 80 100 100 60 40
Cobas SARS-CoV-2 test 5 Commercial ORF1ab, SARS-CoV-2 80 100 100 60 80
Corman et al. (6) 5 In-house N, Sarbeco 100 100 100 60 0
Viasure SARS-CoV-2 real-time PCR detection kit 5 Commercial N, SARS-CoV-2 100 100 100 100 0
Viasure SARS-CoV-2 real-time PCR detection kit 5 Commercial ORF1ab, SARS-CoV-2 100 80 100 100 0
Others 38 Both Various 97 92 79 71 37
(Continued on next page)
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medium for sample preparation and quantifying concentrations with classic rRT-PCR
instead of droplet digital PCR. Based on detection limits for commercial and in-house
rRT-PCR tests (14), the participants in the recently published SARS-CoV-2 EQA (4)
seem to overperform, which may indicate in reality slightly higher sample concen-
trations than those quantified by the authors before shipment. Both routine clinical
laboratories and expert laboratories performed well, considering that suboptimal
sensitivity in EQAs for molecular diagnostics of recently emerged viruses is not
uncommon (2, 15, 16).
Notably, the results indicate that performance can be increased by harmonized
workflows, rather than by the selection of specific extraction or rRT-PCR kits. None of
the individual components of the workflow that were analyzed for this study were able
to significantly influence the overall performance of a laboratory.
The conduction of follow-up EQAs will be essential to further support European lab-
oratories to systematically improve and maintain diagnostic capabilities, while the
need for a robust global detection capability requires global EQA programs.
SUPPLEMENTAL MATERIAL
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39 97 100 100 94 100 100 86 2 24
36 100 100 100 100 100 90 84 0 29
70 100 100 100 100 100 100 90 0 18
50 100 100 100 100 100 88 92 0 15
56 100 100 100 100 100 67 85 0 28
56 100 100 89 100 100 100 88 2 20
33 100 100 100 100 100 100 83 0 31
40 100 100 100 100 100 100 89 0 20
40 100 100 100 100 100 100 87 0 23
40 100 100 100 100 100 80 84 0 30
40 100 100 100 100 100 100 87 0 23
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40 100 100 100 80 100 80 84 4 27
0 100 100 100 100 100 100 80 0 37
39 100 97 100 95 100 NA 82 6 31
aNone of the assays performed significantly better than “Others” considering two-sided Yates’ corrected chi square. Sample 9 was excluded for calculation of the EQA
performances.
bNumber of EQA participants that performed the respective rRT-PCR assay.
cClinically relevant samples that were used to assess laboratory performance in this study. Clinical relevance was given to SARS-CoV-2 samples of different concentrations
and to samples containing other human respiratory viruses that are currently circulating in the human population. Sample no. 9 (SARS-CoV) is currently not circulating in
the human population and therefore is not a core sample. pos., positive; neg., negative.
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